The aim – to study the efficacy and safety of lercanidipine included into different combined pharmacotherapeutic regimens in patients above 60 years.
Material and methods. The study included 123 patients (51 males and 72 females aged 60–80 years) with 2nd–3rd stage arterial hypertension under antihypertensive therapy. The patients were divided into two groups. In the first one the patients received combination of ramipril and hydrochlorothiazide, in the second one – losartan and hydrochlorothiazide. In case in inefficacy of this treatment lercanidipine was added with slow dose titration. Treatment efficacy was assessed taking into account hemodynamic and laboratory parameters.
Results. Treatment with three antihypertensive drugs (AHD) was used in 42 patients from the 1st group and 43 patients from the 2nd one. Target blood pressure (BP) was achieved in 88.1 % patients from the first group and in 81.4 % patients from the second one. In both groups we observed clear decrease of systolic as well as diastolic BP, but in the 1st group these changes were more significant, compared to the 2nd one. However, in patients from the 2nd group better effect of combined therapy upon laboratory parameters was noted, in particular, concerning total cholesterol and uric acid rates.
Conclusion. These results prove about favorable influence of lercanidipine added as the third AHD in elderly patients. In the group of ramipril, hydrochlorothiazide and lercanidipine we observed more significant BP decrease, and in the group of losartan, hydrochlorothiazide and lercanidipine – more favorable changes of total cholesterol and uric acid. These findings should be considered while choosing combined antihypertensive therapy in elderly patients with accompanying risk factors.